Metropolis Healthcare
Metropolis Healthcare Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Metropolis Healthcare
Start SIPMetropolis Healthcare Investment Rating
-
Master Rating:
-
Metropolis Healthcare has an operating revenue of Rs. 1,148.21 Cr. on a trailing 12-month basis. An annual revenue de-growth of -7% needs improvement, Pre-tax margin of 16% is great, ROE of 14% is good. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 44 which is a POOR score indicating inconsistency in earnings, a RS Rating of 31 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 153 indicates it belongs to a poor industry group of Medical-Services and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 264 | 265 | 280 | 257 | 218 |
| Operating Expenses Qtr Cr | 197 | 199 | 205 | 196 | 172 |
| Operating Profit Qtr Cr | 68 | 66 | 75 | 61 | 46 |
| Depreciation Qtr Cr | 22 | 22 | 20 | 20 | 12 |
| Interest Qtr Cr | 6 | 6 | 7 | 8 | 5 |
| Tax Qtr Cr | 8 | 12 | 13 | 7 | 10 |
| Net Profit Qtr Cr | 40 | 33 | 38 | 28 | 63 |
Metropolis Healthcare Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 12
- Bearish Moving Average
- ___
- 4
- 20 Day
- ₹1292.55
- 50 Day
- ₹1286.14
- 100 Day
- ₹1311.44
- 200 Day
- ₹1428.44
- 20 Day
- ₹1295.21
- 50 Day
- ₹1270.08
- 100 Day
- ₹1291.63
- 200 Day
- ₹1379.41
Metropolis Healthcare Resistance and Support
| Resistance | |
|---|---|
| First Resistance | ₹1328.27 |
| Second Resistance | ₹1339.69 |
| Third Resistance | ₹1351.92 |
| RSI | 57.18 |
| MFI | 47.47 |
| MACD Single Line | 5.92 |
| MACD | 9.51 |
| Support | |
|---|---|
| First Resistance | ₹1304.62 |
| Second Resistance | ₹1292.39 |
| Third Resistance | ₹1280.97 |
Metropolis Healthcare Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 181,622 | 5,768,315 | 31.76 |
| Week | 156,011 | 4,830,107 | 30.96 |
| 1 Month | 284,678 | 9,084,060 | 31.91 |
| 6 Month | 249,598 | 8,401,468 | 33.66 |
Metropolis Healthcare Result Highlights
Metropolis Healthcare Synopsis
NSE-Medical-Services
Metropolis Healthcar is involved in the business activities of Activities of independent diagnostic/pathological laboratories. Company’s Total Operating Revenue is Rs. 1066.04 Cr. and Equity Capital is Rs. 10.24 Cr. for the Year ended 31/03/2023. Metropolis Healthcare Ltd. is a Public Limited Listed company incorporated on 01/03/2006 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L73100MH2000PLC192798 and registration number is 192798.| Market Cap | 6,737 |
| Sales | 1,066 |
| Shares in Float | 2.56 |
| No of funds | 173 |
| Yield | 0.61 |
| Book Value | 7.2 |
| U/D Vol ratio | 0.8 |
| LTDebt / Equity | 3 |
| Alpha | -0.09 |
| Beta | 0.78 |
Metropolis Healthcare
| Owner Name | Mar-23 | Dec-22 | Sep-22 | Jun-22 |
|---|---|---|---|---|
| Promoters | 49.75% | 49.76% | 49.76% | 49.79% |
| Mutual Funds | 12.38% | 11.79% | 10.93% | 12.76% |
| Insurance Companies | 0.94% | 0.94% | 0.95% | 1.09% |
| Foreign Portfolio Investors | 25.67% | 23.86% | 25.57% | 23.2% |
| Individual Investors | 8.53% | 9.74% | 9.45% | 9.26% |
| Others | 2.73% | 3.91% | 3.34% | 3.9% |
Metropolis Healthcare Management
| Name | Designation |
|---|---|
| Dr. Sushil Kanubhai Shah | Chairman & Executive Director |
| Mrs. Ameera Sushil Shah | Managing Director |
| Mr. Hemant Sachdev | Non Exe.Non Ind.Director |
| Mr. Vivek Gambhir | Ind. Non-Executive Director |
| Mr. Sanjay Bhatnagar | Ind. Non-Executive Director |
| Mr. Milind Shripad Sarwate | Ind. Non-Executive Director |
| Ms. Anita Ramachandran | Ind. Non-Executive Director |
Metropolis Healthcare Forecast
Price Estimates
Metropolis Healthcare Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-05-16 | Audited Results | |
| 2023-02-10 | Quarterly Results & Interim Dividend | |
| 2022-11-08 | Quarterly Results | |
| 2022-08-10 | Quarterly Results | |
| 2022-07-18 | Others | Inter alia, to consider and approve the revised Audited Standalone Financial results of the Company for the Quarter and Year ended March 31, 2022. per share(400%)Interim Dividend |
| Date | Purpose | Remarks |
|---|---|---|
| 2023-02-23 | INTERIM | Rs.8.00 per share(400%)Interim Dividend (Revised) |
| 2022-02-22 | INTERIM | Rs.8.00 per share(400%)Interim Dividend |
| 2021-02-19 | INTERIM | Rs.8.00 per share(400%)Interim Dividend |
Metropolis Healthcare FAQs
What is Share Price of Metropolis Healthcare ?
Metropolis Healthcare share price is ₹1310 As on 06 June, 2023 | 22:11
What is the Market Cap of Metropolis Healthcare ?
The Market Cap of Metropolis Healthcare is ₹6711.4 Cr As on 06 June, 2023 | 22:11
What is the P/E ratio of Metropolis Healthcare ?
The P/E ratio of Metropolis Healthcare is 47 As on 06 June, 2023 | 22:11
What is the PB ratio of Metropolis Healthcare ?
The PB ratio of Metropolis Healthcare is 6.8 As on 06 June, 2023 | 22:11